Update on the clinical utility and optimal use of cefditoren

International Journal of General Medicine

Volumn 5, Issue , 2012, Pages 455-464

  Barberán, José ^a   Aguilar, Lorenzo ^b   Giménez, María José ^b  

^a HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

^b SCHOOL OF MEDICINE   (Spain)

Author keywords

Acute exacerbations of chronic bronchitis; Community acquired pneumonia; Otitis media; Pharyngotonsillitis; Sinusitis

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFDITOREN; CEFDITOREN PIVOXIL; CEFPODOXIME; CEFUROXIME AXETIL; CLARITHROMYCIN;

ABDOMINAL PAIN; ACUTE OTITIS MEDIA; ACUTE SINUSITIS; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; HEMATURIA; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHARMACODYNAMICS; REVIEW; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TONSILLITIS; VAGINITIS;

EID: 84875410043     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S25989     Document Type: Review

References (90)

1. World Health Organization, Department of Communicable Disease Surveillance and Response. WHO Global Strategy for Containment of Antimicrobial Resistance. Geneva: World Health Organization; 2001. Available from: http://www.who.int/csr/resources/publications/ drugresist/en/EGlobal_Strat.pdf. Accessed February 8, 2012.
2. Levy-Hara G, Amábile-Cuevas CF, Gould I, et al; for the International Society of Chemotherapy Antimicrobial Stewardship Working Group. "Ten Commandments" for the appropriate use of antibiotics by the practicing physician in an outpatient setting. Front Microbiol. 2011;2:230.
3. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother. 2009;64(Suppl 1):i29-i36.
4. Mouton JW, Ambrose PG, Canton R, et al. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat. 2011;14(2):107-117.
5. Huovinen P, Cars O. Control of antimicrobial resistance: time for action. The essentials of control are already well known. BMJ. 1998; 317(7159):613-614.
6. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med. 2010;16(3):217-225.
7. Fenoll A, Aguilar L, Granizo JJ, et al. Has the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae? J Antimicrob Chemother. 2008;62(6):1430-1433.
8. Fenoll A, Granizo JJ, Aguilar L, et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol. 2009;47(4):1012-1020.
9. Fenoll A, Aguilar L, Vicioso MD, Gimenez MJ, Robledo O, Granizo JJ. Increase in serotype 19A prevalence and amoxicillin non-susceptibility among paediatric Streptococcus pneumoniae isolates from middle ear fluid in a passive laboratory-based surveillance in Spain, 1997-2009. BMC Infect Dis. 2011;11:239.
10. Farrell DJ, Couturier C, Hryniewicz W. Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003-2004). Int J Antimicrob Agents. 2008;31(3):245-249.
11. Lynch JP 3rd, Zhanel GG. Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy. Semin Respir Crit Care Med. 2005;26(6):575-616.
12. Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents. 2010;36(3):197-204.
13. Granizo JJ, Aguilar L, Casal J, Dal-Ré R, Baquero F. Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997). J Antimicrob Chemother. 2000;46(6): 959-964.
14. Richter SS, Heilmann KP, Beekmann SE, et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis. 2005;41(5):599-608.
15. Chan JC, Chu YW, Chu MY, Cheung TK, Lo JY. Epidemiological analysis of Streptococcus pyogenes infections in Hong Kong. Pathology. 2009;41(7):681-686.
16. Gracia M, Díaz C, Coronel P, et al. Antimicrobial susceptibility of Streptococcus pyogenes in Central, Eastern, and Baltic European Countries, 2005 to 2006: the cefditoren surveillance program. Diagn Microbiol Infect Dis. 2009;64(1):52-56.
17. Pérez-Trallero E, Martín-Herrero JE, Mazón A, et al; Spanish Surveillance Group for Respiratory Pathogens. Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). Antimicrob Agents Chemother. 2010;54(7):2953-2959.
18. Yan SS, Fox ML, Holland SM, Stock F, Gill VJ, Fedorko DP. Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes: identification of gyrA and parC and specification of point mutations associated with resistance. Antimicrob Agents Chemother. 2000;44(11):3196-3198.
19. Biedenbach DJ, Toleman MA, Walsh TR, Jones RN. Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinoloneresistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004). Diagn Microbiol Infect Dis. 2006;55(2):119-127.
20. Richter SS, Diekema DJ, Heilmann KP, et al. Fluoroquinolone resistance in Streptococcus pyogenes. Clin Infect Dis. 2003;36(3):380-383.
21. Reinert RR, Lütticken R, Al-Lahham A. High-level fluoroquinolone resistance in a clinical Streptoccoccus pyogenes isolate in Germany. Clin Microbiol Infect. 2004;10(7):659-662.
22. Malhotra-Kumar S, Van Heirstraeten L, Lammens C, Chapelle S, Goossens H. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin. J Antimicrob Chemother. 2009;63(5):886-894.
23. Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev. 2007;20(2):368-389.
24. Sahm DF, Brown NP, Thornsberry C, Jones ME. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. Postgrad Med. 2008;120(3 Suppl 1):16-24.
25. Sahm DF, Brown NP, Draghi DC, Evangelista AT, Yee YC, Thornsberry C. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005. Postgrad Med. 2008;120(3 Suppl 1):8-15.
26. Jansen WT, Verel A, Beitsma M, Verhoef J, Milatovic D. Longitudinal European surveillance study of antibiotic resistance of Haemophilus influenzae. J Antimicrob Chemother. 2006;58(4):873-877.
27. Jansen WT, Verel A, Beitsma M, Verhoef J, Milatovic D. Surveillance study of the susceptibility of Haemophilus influenzae to various antibacterial agents in Europe and Canada. Curr Med Res Opin. 2008;24(10):2853-2861.
28. Kishii K, Chiba N, Morozumi M, et al. Diverse mutations in the ftsI gene in ampicillin-resistant Haemophilus influenzae isolates from pediatric patients with acute otitis media. J Infect Chemother. 2010;16(2):87-93.
29. Ito M, Hotomi M, Maruyama Y, et al. Clonal spread of beta-lactamaseproducing amoxicillin-clavulanate-resistant (BLPACR) strains of nontypeable Haemophilus influenzae among young children attending a day care in Japan. Int J Pediatr Otorhinolaryngol. 2010;74(8):901-906.
30. Suzuki K, Nishimaki K, Okuyama K, et al. Trends in antimicrobial susceptibility of in the Tohoku district of Japan: a longitudinal analysis from 1998 to 2007. Tohoku J Exp Med. 2010;220(1):47-57.
31. Kang JH, Lee SY, Kim JH, Hur JK, Lee KY. In vitro antimicrobial activity of cefditoren and other oral antibiotics against Streptococcus pneumoniae, isolated from children with community acquired respiratory tract infections. Jpn J Antibiot. 2010;63(1):11-17.
32. Biedenbach DJ, Jones RN. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations. Diagn Microbiol Infect Dis. 2009;64(2):202-212.
33. Fritsche TR, Biedenbach DJ, Jones RN. Update of the activity of cefditoren and comparator oral beta-lactam agents tested against community-acquired Streptococcus pneumoniae isolates (USA, 2004-2006). J Chemother. 2008;20(2):170-174.
34. Stefani S, Mezzatesta ML, Fadda G, et al. Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in Italy. J Chemother. 2008;20(5):561-569.
35. Tempera G, Furneri PM, Ferranti C, et al. In vitro activity of cefditoren versus other antibiotics against S. pneumoniae clinical strains isolated in Italy. Int J Immunopathol Pharmacol. 2010;23(3):833-840.
36. Tempera G, Furneri PM, Carlone NA, et al. Antibiotic susceptibility of respiratory pathogens recently isolated in Italy: focus on cefditoren. J Chemother. 2010;22(3):153-159.
37. Seral C, Suárez L, Rubio-Calvo C, et al. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain. Diagn Microbiol Infect Dis. 2008;62(2):210-215.
38. Fenoll A, Giménez MJ, Robledo O, et al. Activity of cefditoren against clinical isolates of Streptococcus pneumoniae showing nonsusceptibility to penicillins, cephalosporins, macrolides, ketolides or quinolones. Int J Antimicrob Agents. 2007;29(2):224-226.
39. Fenoll A, Aguilar L, Robledo O, et al. Influence of the 3-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media. J Antimicrob Chemother. 2007;60(2):323-327.
40. Fenoll A, Giménez MJ, Robledo O, et al. Influence of penicillin/ amoxicillin non-susceptibility on the activity of third-generation cephalosporins against Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis. 2008;27(1):75-80.
41. Fenoll A, Giménez MJ, Robledo O, et al. In vitro activity of oral cephalosporins against pediatric isolates of Streptococcus pneumoniae non-susceptible to penicillin, amoxicillin or erythromycin. J Chemother. 2008;20(2):175-179.
42. Kozlov RS, Sivaya OV, Shevelev AN. Perspective of new cephalosporins for treatment of pneumococcal infections. Pulmonology. 2011;3:53-58. Article in Russian, htpp://www.pulmonology.ru.
43. Sevillano D, Giménez MJ, Cercenado E, et al. Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers. Antimicrob Agents Chemother. 2009;53(1):267-270.
44. Gracia M, Díaz C, Coronel P, et al. Antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis isolates in eight Central, East and Baltic European countries in 2005-2006: results of the Cefditoren Surveillance Study. J Antimicrob Chemother. 2008;61(5):1180-1181.
45. Harimaya A, Yokota S, Sato K, Himi T, Fujii N. Remarkably high prevalence of fts I gene mutations in Haemophilus influenzae isolates from upper respiratory tract infections in children of the Sapporo district, Japan. J Infect Chemother. 2008;14(3):223-227.
46. García-de-Lomas J, Lerma M, Cebrián L, et al. Influence of Haemophilus influenzae beta-lactamase production and/or ftsI gene mutations on in vitro activity of and susceptibility rates to aminopenicillins and second-and third-generation cephalosporins. Int J Antimicrob Agents. 2007;30(2):190-192.
47. Biedenbach DJ, Jones RN, Fritsche TR. Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States. Diagn Microbiol Infect Dis. 2008;61(2):240-244.
48. Wellington K, Curran MP. Cefditoren pivoxil: a review of its use in the treatment of bacterial infections. Drugs. 2004;64(22): 2597-2618.
49. Sádaba B, Azanza JR, Quetglas EG, et al. Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice-and thrice-daily regimens in healthy volunteers: a phase I study. Rev Esp Quimioter. 2007;20(1):51-60.
50. Lodise TP, Kinzig-Schippers M, Drusano GL, et al. Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid. Antimicrob Agents Chemother. 2008;52(6): 1945-1951.
51. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1-10.
52. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 2000;160(10): 1399-1408.
53. Granizo JJ, Sádaba B, Honorato J, et al. Monte Carlo simulation describing the pharmacodynamic profile of cefditoren in plasma from healthy volunteers. Int J Antimicrob Agents. 2008;31(4):396-398.
54. Cafini F, Yuste J, Giménez MJ, et al. Enhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant S. pneumoniae (serotypes 6B, 19F and 23F) in a sepsis model. PLoS One. 2010; 5(8):e12041.
55. Tsumura N, Nagai K, Hidaka H, et al. Antibiotic therapy against acute tonsillopharyngitis in children due to group A beta-hemolytic streptococci: comparison of clinical efficacy, the bactericidal effects, and effects on oral flora between cefditoren pivoxil for 5 days and amoxicillin for 10 days. Jpn J Antibiot. 2011;64(3):179-190. Japanese.
56. Ozaki T, Nishimura N, Suzuki M, et al. Five-day oral cefditoren pivoxil versus 10-day oral amoxicillin for pediatric group A streptococcal pharyngotonsillitis. J Infect Chemother. 2008;14(3):213-218.
57. Sakata H. A multicenter study of 7-day cefditoren pivoxil treatment for group A streptococcal infection. Jpn J Antibiot. 2007;60(5):257-263. Japanese.
58. Kawamata S, Yamada H, Sato Y, Sasagawa Y, Iwama Y, Matumoto M. Evaluation of the safety and efficacy of cefditoren pivoxil fine granules for pediatric use in pediatric patients with laryngopharyngitis and tonsillitis caused by Streptococcus pyogenes. Jpn J Antibiot. 2010;63(4): 299-311. Japanese.
59. Ogawa T, Terao Y, Okuni H, et al. Biofilm formation or internalization into epithelial cells enable Streptococcus pyogenes to evade antibiotic eradication in patients with pharyngitis. Microb Pathog. 2011; 51(1-2):58-68.
60. Kaplan EL, Tucker RM, Poling TL, Marsh D, Chow C. Managing group A streptococcal infection. A multicenter comparison of cefditoren pivoxil and penicillin VK. J Resp Dis. 2001;22(Suppl 8): S60-S64.
61. Gooch W, Marsh D, Slickler T, Hunt B. Cefditoren is safe and effective treatment for streptococcal pharyngitis. In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto 2000. Abstract 837. Washington DC: American Society for Microbiology.
62. Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L. Efficacy of cefditoren in the treatment of upper respiratory tract infections: a pooled analysis of six clinical trials. Rev Esp Quimioter. 2008;21(1):14-21.
63. Chole RA, Faddis BT. Anatomical evidence of microbial biofilms in tonsillar tissues: a possible mechanism to explain chronicity. Arch Otolaryngol Head Neck Surg. 2003;129(6):634-636.
64. Swidsinski A, Göktas O, Bessler C, et al. Spatial organisation of microbiota in quiescent adenoiditis and tonsillitis. J Clin Pathol. 2007;60(3):253-260.
65. Galli J, Calò L, Ardito F, et al. Biofilm formation by Haemophilus influenzae isolated from adeno-tonsil tissue samples, and its role in recurrent adenotonsillitis. Acta Otorhinolaryngol Ital. 2007;27(3): 134-138.
66. Sevillano D, Aguilar L, Alou L, et al. Beta-lactam effects on mixed cultures of common respiratory isolates as an approach to treatment effects on nasopharyngeal bacterial population dynamics. PLoS One. 2008;3(12): e3846.
67. Pichichero ME, Casey JR. Systematic review of factors contributing to penicillin treatment failure in Streptococcus pyogenes pharyngitis. Otolaryngol Head Neck Surg. 2007;137(6):851-857.
68. Kikuta H, Shibata M, Nakata S, et al. Comparative study of 5-day and 10-day cefditoren pivoxil treatments for recurrent group A beta-hemolytic Streptococcus pharyngitis in children. Int J Pediatr. 2009;2009:863608.
69. Poachanukoon O, Kitcharoensakkul M. Efficacy of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigatorblinded, controlled trial. Clin Ther. 2008;30(10):1870-1879.
70. Chow J, Russell M, Volk S, Chow C. Efficacy of cefditoren pivoxil (CDTR) versus amoxicillin/clavulanate (AMX/CLV) in acute maxillary sinusitis (AMS). In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto 2000. Abstract 835. Washington DC: American Society for Microbiology.
71. Kawamata S, Yamada H, Sato Y, Sasagawa Y, Iwama Y, Matumoto M. Evaluation of the safety and efficacy of cefditoren pivoxil fine granules for pediatric use in pediatric patients with acute otitis media. Jpn J Antibiot. 2010;63(3):207-223. Japanese.
72. Sakata H. Comparative study on bacterial eradication rate and clinical efficacy of CDTR, CFPN, and FRPM for treatment of children with otitis media and lower respiratory tract infection due to Streptococcus pneumoniae and Haemophilus influenzae. Jpn J Antibiot. 2001; 54 Suppl B:96. Japanese.
73. Ito M, Furukawa M. High-dose cefditren therapy for children with acute otitis media that had Streptococcus pneumoniae and Haemophilus influenzae isolated from the nasopharynx. Jpn J Antibiot. 2001; 54 Suppl B:37-38. Japanese
74. Sugita R, Deguchi K, Kimura S, et al. Efficacy of cefditoren pivoxil in the treatment of acute otitis media due to benzylpenicillin-insensitive Streptococcus pneumoniae. Jpn J Antibiot. 1996;49(4):386-398. Japanese.
75. Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials. Clin Ther. 2006; 28(12):2061-2069.
76. Granizo JJ, Aguilar L, Gimenez MJ, Coronel P, Gimeno M, Prieto J. Safety profile of cefditoren. A pooled analysis of data from clinical trials in community-acquired respiratory tract infections. Rev Esp Quimioter. 2009;22(2):57-61.
77. Todesco L, Bodmer M, Vonwil K, Häussinger D, Krähenbühl S. Interaction between pivaloylcarnitine and L-carnitine transport into L6 cells overexpressing hOCTN2. Chem Biol Interact. 2009;180(3): 472-477.
78. Brass EP, Mayer MD, Mulford DJ, Stickler TK, Hoppel CL. Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil. Clin Pharmacol Ther. 2003;73(4):338-347.
79. Fujii R, Chiba S, Numazaki K, et al. Effect of cefditoren pivoxil on carnitine metabolism in pediatric patients. Jpn J Antibiot. 1993; 46(10):926-937. Erratum in: Jpn J Antibiot. 1994;47(9):1240. Japanese.
80. Kim H, Chu K, Jung KH, Lee ST, Kim JM, Lee SK. Acquired encephalopathy associated with carnitine deficiency after cefditoren pivoxil administration. Neurol Sci. 2012. Epub Jan 19.
81. Makino Y, Sugiura T, Ito T, Sugiyama N, Koyama N. Carnitine-associated encephalopathy caused by long-term treatment with an antibiotic containing pivalic acid. Pediatrics. 2007;120(3):e739-e741.
82. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. CLSI document M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2009.
83. Murphy TF. The role of bacteria in airway inflammation in exacerbations of chronic obstructive pulmonary disease. Curr Opin Infect Dis. 2006;19(3):225-230.
84. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest. 2005;127(6):2231-2236.
85. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347(7):465-471.
86. Fenoll A, Aguilar L, Giménez MJ, et al. Susceptibility of recently collected Spanish pneumococci nonsusceptible to oral penicillin from serotypes not included in the 7-valent conjugate vaccine. Antimicrob Agents Chemother. 2010;54(6):2696-2698.
87. Barberán J, Mensa J. Cefditoren and community-acquired lower respiratory tract infections (corrected). Rev Esp Quimioter. 2009;22(3): 144-150. Spanish.
88. Casey JR, Pichichero ME. The evidence base for cephalosporin superiority over penicillin in streptococcal pharyngitis. Diagn Microbiol Infect Dis. 2007;57(Suppl 3):39S-45S.
89. Bisno AL. Are cephalosporins superior to penicillin for treatment of acute streptococcal pharyngitis? Clin Infect Dis. 2004;38:1535-1537.
90. Shulman ST, Gerber MA. So what's wrong with penicillin for strep throat? Pediatrics. 2004;113(6):1816-1819.